<div class="p4l_caption"><div class="p4l_captionTitle"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3137639/" ref="ordinalpos=1581&amp;ncbi_uid=3087802&amp;link_uid=PMC3137639" image-link="/pmc/articles/PMC3137639/figure/F2/" class="imagepopup">Figure 2. Effects of RTKIs and <span class="highlight" style="background-color:">pathway</span> inhibitors on Akt-RSK-S6 kinase <span class="highlight" style="background-color:">signaling</span>.  From: Akt-RSK-S6-kinase <span class="highlight" style="background-color:">Signaling</span> Networks Activated by Oncogenic Receptor Tyrosine Kinases. </a></div><br /><div class="p4l_captionBody">(A) Strategy of probing signaling pathways with different inhibitors. Wort, wortmannin; Rapa, rapamycin. (B) Immunoblotting of three cancer cell lines treated with the indicated inhibitors. (C) Immunoblotting showing the effect of inhibitors on Akt, RSK, S6, and ERK phosphorylation. (D) Confirmation of MS/MS results by immunoblotting wih phosphospecific antibodies. Actin was used as loading control.</div></div>